Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free EVOXW Stock Alerts

Evox Therapeutics (EVOXW) Competitors

Evox Therapeutics logo
$0.37 +0.00 (+0.32%)
Closing price 09/4/2026 09:19 AM Eastern
Extended Trading
$0.37 0.00 (0.00%)
As of 09/4/2026 09:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

EVOXW vs. AGD, AWP, THQ, ACP, and THW

Should you buy Evox Therapeutics stock or one of its competitors? Evox Therapeutics's main competitors and comparable companies include Abrdn Global Dynamic Dividend Fund (AGD), abrdn Global Premier Properties Fund (AWP), Abrdn Healthcare Opportunities Fund (THQ), Abrdn Income Credit Strategies Fund (ACP), and Abrdn World Healthcare Fund (THW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does Evox Therapeutics compare to Abrdn Global Dynamic Dividend Fund?

Abrdn Global Dynamic Dividend Fund (NYSE:AGD) and Evox Therapeutics (NASDAQ:EVOXW) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abrdn Global Dynamic Dividend Fund$75.72MN/AN/AN/AN/A
Evox TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Abrdn Global Dynamic Dividend FundN/A N/A N/A
Evox Therapeutics N/A N/A N/A

In the previous week, Abrdn Global Dynamic Dividend Fund and Abrdn Global Dynamic Dividend Fund both had 1 articles in the media. Abrdn Global Dynamic Dividend Fund's average media sentiment score of 1.26 beat Evox Therapeutics' score of 0.75 indicating that Abrdn Global Dynamic Dividend Fund is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abrdn Global Dynamic Dividend Fund
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Evox Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Abrdn Global Dynamic Dividend Fund beats Evox Therapeutics on 2 of the 2 factors compared between the two stocks.

How does Evox Therapeutics compare to abrdn Global Premier Properties Fund?

abrdn Global Premier Properties Fund (NYSE:AWP) and Evox Therapeutics (NASDAQ:EVOXW) are both finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
abrdn Global Premier Properties FundN/A N/A N/A
Evox Therapeutics N/A N/A N/A

In the previous week, Evox Therapeutics had 1 more articles in the media than abrdn Global Premier Properties Fund. MarketBeat recorded 1 mentions for Evox Therapeutics and 0 mentions for abrdn Global Premier Properties Fund. Evox Therapeutics' average media sentiment score of 0.75 beat abrdn Global Premier Properties Fund's score of 0.00 indicating that Evox Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
abrdn Global Premier Properties Fund Neutral
Evox Therapeutics Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
abrdn Global Premier Properties Fund$60.73MN/AN/AN/AN/A
Evox TherapeuticsN/AN/AN/AN/AN/A

Summary

Evox Therapeutics beats abrdn Global Premier Properties Fund on 2 of the 3 factors compared between the two stocks.

How does Evox Therapeutics compare to Abrdn Healthcare Opportunities Fund?

Evox Therapeutics (NASDAQ:EVOXW) and Abrdn Healthcare Opportunities Fund (NYSE:THQ) are both finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evox TherapeuticsN/AN/AN/AN/AN/A
Abrdn Healthcare Opportunities Fund-$28.02MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Evox TherapeuticsN/A N/A N/A
Abrdn Healthcare Opportunities Fund N/A N/A N/A

In the previous week, Evox Therapeutics had 1 more articles in the media than Abrdn Healthcare Opportunities Fund. MarketBeat recorded 1 mentions for Evox Therapeutics and 0 mentions for Abrdn Healthcare Opportunities Fund. Evox Therapeutics' average media sentiment score of 0.75 beat Abrdn Healthcare Opportunities Fund's score of 0.00 indicating that Evox Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Evox Therapeutics Positive
Abrdn Healthcare Opportunities Fund Neutral

Summary

Evox Therapeutics beats Abrdn Healthcare Opportunities Fund on 3 of the 3 factors compared between the two stocks.

How does Evox Therapeutics compare to Abrdn Income Credit Strategies Fund?

Evox Therapeutics (NASDAQ:EVOXW) and Abrdn Income Credit Strategies Fund (NYSE:ACP) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Evox Therapeutics had 1 more articles in the media than Abrdn Income Credit Strategies Fund. MarketBeat recorded 1 mentions for Evox Therapeutics and 0 mentions for Abrdn Income Credit Strategies Fund. Evox Therapeutics' average media sentiment score of 0.75 beat Abrdn Income Credit Strategies Fund's score of 0.00 indicating that Evox Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Evox Therapeutics Positive
Abrdn Income Credit Strategies Fund Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evox TherapeuticsN/AN/AN/AN/AN/A
Abrdn Income Credit Strategies Fund$85.32MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Evox TherapeuticsN/A N/A N/A
Abrdn Income Credit Strategies Fund N/A N/A N/A

Summary

Evox Therapeutics beats Abrdn Income Credit Strategies Fund on 2 of the 3 factors compared between the two stocks.

How does Evox Therapeutics compare to Abrdn World Healthcare Fund?

Abrdn World Healthcare Fund (NYSE:THW) and Evox Therapeutics (NASDAQ:EVOXW) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Company Net Margins Return on Equity Return on Assets
Abrdn World Healthcare FundN/A N/A N/A
Evox Therapeutics N/A N/A N/A

In the previous week, Evox Therapeutics had 1 more articles in the media than Abrdn World Healthcare Fund. MarketBeat recorded 1 mentions for Evox Therapeutics and 0 mentions for Abrdn World Healthcare Fund. Evox Therapeutics' average media sentiment score of 0.75 beat Abrdn World Healthcare Fund's score of 0.00 indicating that Evox Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Abrdn World Healthcare Fund Neutral
Evox Therapeutics Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abrdn World Healthcare Fund$86.53MN/AN/AN/AN/A
Evox TherapeuticsN/AN/AN/AN/AN/A

Summary

Evox Therapeutics beats Abrdn World Healthcare Fund on 2 of the 3 factors compared between the two stocks.

Get Evox Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVOXW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVOXW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVOXW vs. The Competition

Export
MetricEvox TherapeuticsCapital Markets IndustryFinance SectorNASDAQ Exchange
Market CapN/A$5.74B$14.31B$12.93B
Dividend YieldN/A7.38%5.88%8.90%
P/E RatioN/A31.6726.1925.45
Price / SalesN/A1,221.45517.6179.33
Price / CashN/A48.2139.5952.28
Price / BookN/A1.982.136.17
Net IncomeN/A$419.47M$1.32B$350.08M
7 Day PerformanceN/A7.28%3.84%-0.14%
1 Month Performance-0.27%0.60%1.61%1.02%
1 Year PerformanceN/A7.46%11.96%14.51%

Evox Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVOXW
Evox Therapeutics
N/A$0.37
+0.3%		N/AN/A$0.00N/AN/AN/A
AGD
Abrdn Global Dynamic Dividend Fund
N/A$12.42
+1.0%		N/A-0.2%$0.00$75.72MN/AN/A
AWP
abrdn Global Premier Properties Fund
N/A$11.70
-0.8%		N/A-3.4%$0.00$60.73MN/AN/A
THQ
Abrdn Healthcare Opportunities Fund
N/A$19.75
-0.8%		N/A+16.1%$0.00-$28.02MN/A1,088
ACP
Abrdn Income Credit Strategies Fund
N/A$4.96
-2.6%		N/A-15.9%$0.00$85.32MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EVOXW) was last updated on 9/5/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel